Technical Analysis for SYRS - Syros Pharmaceuticals, Inc.

Grade Last Price % Change Price Change
D 6.10 1.50% 0.09
SYRS closed up 1.5 percent on Monday, March 18, 2024, on 76 percent of normal volume. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.
1 Watcher
Watchlist Portfolio

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Strong Up Down Down

Date Alert Name Type % Chg
Lower Bollinger Band Walk Weakness 0.00%
Oversold Stochastic Weakness 0.00%
Narrow Range Bar Range Contraction 1.50%
Lower Bollinger Band Walk Weakness 1.50%
Inside Day Range Contraction 1.50%
Below Lower BB Weakness 1.50%
Lower Bollinger Band Touch Weakness 1.50%
Oversold Stochastic Weakness 1.50%
Lower Bollinger Band Walk Weakness 1.16%
Below Lower BB Weakness 1.16%

   Recent Intraday Alerts

Alert Time
Rose Above Previous Day's High about 13 hours ago
Rose Above Lower Bollinger Band about 13 hours ago
Up 3% about 13 hours ago
Up 2% about 13 hours ago
Up 1% about 13 hours ago

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Syros Pharmaceuticals, Inc. Description

Syros Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing medicines that control genes to transform the lives of patients with cancer, immune-mediated diseases, and other diseases. The company's gene control platform identifies gene control targets linked to genomically defined patient populations and drugging gene control targets; identifies potential new drug targets across a range of diseases; provides lens for diagnosing and segmenting patients, including those with complex/multi-factorial diseases; and allows users to advance a wave of medicines with the potential to influence multiple drivers of disease through a single target. Its pipeline includes SY-1425, a selective RARa agonist for genomically defined subsets of patients with relapsed or refractory acute myeloid leukemia and relapsed high-risk myelodysplastic syndrome; and SY-1365, a selective CDK7 inhibitor for acute leukemia. Syros Pharmaceuticals, Inc. was formerly known as LS22, Inc. Syros Pharmaceuticals, Inc. was founded in 2011 and is based in Cambridge, Massachusetts.


Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Biopharmaceutical Cancer Disease Medication Acute Myeloid Leukemia Leukemia Myelodysplastic Syndrome Immune Mediated Diseases Acute Leukemia Refractory Acute Myeloid Leukemia

Is SYRS a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 8.17
52 Week Low 2.0902
Average Volume 196,554
200-Day Moving Average 4.47
50-Day Moving Average 7.02
20-Day Moving Average 6.95
10-Day Moving Average 6.56
Average True Range 0.45
RSI (14) 35.48
ADX 25.62
+DI 17.28
-DI 26.04
Chandelier Exit (Long, 3 ATRs) 6.61
Chandelier Exit (Short, 3 ATRs) 7.20
Upper Bollinger Bands 7.98
Lower Bollinger Band 5.93
Percent B (%b) 0.08
BandWidth 29.37
MACD Line -0.23
MACD Signal Line -0.08
MACD Histogram -0.1515
Fundamentals Value
Market Cap 158.64 Million
Num Shares 26 Million
EPS 0.85
Price-to-Earnings (P/E) Ratio 7.18
Price-to-Sales 20.62
Price-to-Book 5.06
PEG Ratio 0.00
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 6.45
Resistance 3 (R3) 6.45 6.34 6.39
Resistance 2 (R2) 6.34 6.25 6.34 6.37
Resistance 1 (R1) 6.22 6.19 6.28 6.22 6.35
Pivot Point 6.11 6.11 6.14 6.10 6.11
Support 1 (S1) 5.99 6.02 6.05 5.98 5.85
Support 2 (S2) 5.88 5.96 5.87 5.83
Support 3 (S3) 5.76 5.88 5.81
Support 4 (S4) 5.75